Delivering Unprecedented Access to Biosimilars in Global Markets
  • Building a focused, sustainable and profitable
    biosimilar business
  • Improving patient access to important, cost-effective
    medicines worldwide
  • Advancing our products through strategic partnerships
    to maximize future value
Who We Are

EPIRUS is a biopharmaceutical company building a focused, sustainable and profitable biosimilar business by improving patient access to cost-effective medicines worldwide.  Our ability to deliver on this mission is anchored in our strong technical platform and our focus on value retention through effective navigation of diverse regulatory, legal and commercial markets globally.  We are currently progressing a pipeline of six monoclonal antibodies for autoimmune / inflammatory and rare diseases.

Learn More


September 9, 2015

EPIRUS Biopharmaceuticals Expands Biosimilar Pipeline and Capabilities Through Acquisition of Bioceros

August 7, 2015

EPIRUS Biopharmaceuticals Reports Second Quarter 2015 Financial Results



September 9, 2015

EPIRUS Announces Acquisition of Bioceros

August 11, 2015

EPIRUS Presents at Wedbush PacGrow Healthcare Conference


Bookmark and Share